Table 1.
Experimental protocols for motor neuron induction from human embryonic and induced pluripotent stem cells
| References | Starting cells |
Neural induction |
MN differentiation |
MN maturation |
Duration | ||||
|---|---|---|---|---|---|---|---|---|---|
| Medium | Factors | Obtained cells | Medium | Factors | Medium | Factors | |||
| Amoroso et al. [39] |
ESCs and iPSCs |
ESC mediuma |
Y27632, bFGF, LDN193189, and SB435142 |
Embryoid bodies |
Neural induction mediumb |
RA, ascorbic acid, BDNF, C25II modified Shh, SAG, HAG, or purmorphamine |
Neurobasal medium |
IGF1, GDNF, CNTF, and B27 |
20-30 days |
| Boulting et al. [40] |
ESCs and iPSCs |
ESC medium with 10% KO replacement |
bFGF and Y27632 |
Embryoid bodies |
Neural induction mediumb supplemented with bFGF |
RA, ascorbic acid, db-cAMP, and HAG |
Neurobasal medium |
BDNF, GDNF, and CNTF |
29 days |
| Burkhardt et al. [41] |
iPSCs |
DMEM/F12 supplemented with N2, B27, and NEAA |
Y27632, Dorsomorphin dihydrochloride |
Embryoid bodies |
DMEM/F12, GLUTAMAX, N2, B27 serum-free supplement, D-Glucose, and ascorbic acid |
SAG, RA, and DAPT (only for 4 days) |
DMEM/F12, GLUTAMAX |
CNTF, BDNF, and GDNF |
32 days |
| N2, B27 serum free supplement, D-Glucose, and ascorbic acid | |||||||||
| Corti et al. [25] |
iPSCs |
DMEM/F12, NEAA, N2, and heparin |
RA |
Neural rosette |
DMEM/F12, NEAA, N2, and heparin |
RA and Shh |
DMEM/F12, NEAA, N2, and heparin |
BDNF, GDNF, and IGF1 |
~24 days |
| Hester et al. [42] |
ESCs and iPSCs |
DMEM/F12, N2, and 10% KO serum |
- |
Embryoid bodies then neural rosette |
DMEM/F12 with N2 |
RA, Shh, forskolin, B27, and adenovirus |
- |
- |
~40 days |
| Hu and Zhang [43] |
ESCs |
DMEM/F12, KO serum replacement, NEAA, L-Glu, and BME |
- |
Floating embryoid bodies |
Neural differentiation medium (DMEM/F12, N2, NEAA, and heparin) |
Shh or purmorphamine, RA, B27, cAMP, ascorbic acid, BDNF, GDNF, and IGF1 |
Neural differentiation medium (DMEM/F12, N2, NEAA, and heparin) |
cAMP, ascorbic acid, BDNF, GDNF, and IGF1 |
~40 days |
| Karumbayaram et al. [44] |
iPSCs and ESCs |
ESC medium without FGF2 |
- |
Embryoid bodies/neural rosette |
ESC medium without FGF2 |
RA and purmorphamine |
DMEM/F12 and N2 |
GDNF, BDNF, CNTF, Shh, and RA |
35-49 days |
| Reinhardt et al. [29] |
iPSCs and ESCs |
ESC mediuma and then expansion medium (DMEM/F12, N2, B27, pen/strep, and L-Glu) |
For induction: SB435142, Dorsomorphine, CHIR, and purmorphamine |
Embryoid bodies (smNPC) |
Expansion medium (DMEM/F12, N2, B27, pen/strep, and L-Glu) |
Purmorphamine and RA |
Expansion N2, B27 |
BDNF, GDNF, db-cAMP, RA, and purmorphamine |
>40 days |
| For expansion: ascorbic acid, CHIR99021, and purmorphamine | |||||||||
| Sareen et al. [45] |
iPSCs |
Neural differentiation medium (DMEM, B27, vitamin A, and N2) |
RA |
Embryoid bodies |
Neurobasal medium, B27, and N2 |
RA and purmorphamine |
DMEM/F12 and B27 |
RA, purmorphamine, db-cAMP, ascorbic acid, BDNF, and GDNF |
>40 days |
| Takazawa et al. [37] |
ESCs |
ESC mediuma and then DMEM/F12, N2, NEAA, L-Glu, and heparin |
Y27632, bFGF, and recombinant mouse Noggin |
Embryoid bodies |
Wnt3a-L-cell conditioned medium |
RA, ascorbic acid, db-cAMP, and recombinant mouse Shh (C25II) |
Neurobasal medium with N2, B27, Glu, and NEAA |
Ascorbic acid, db-cAMP, RA, Shh, BDNF, GDNF, and IGF1 |
>31 days |
| Wada et al. [46] |
ESCs |
ESC mediuma and FGF2 |
Noggin and dorsomorphin |
Neural rosette |
DMEM/F12, N2B27 |
Shh or SAG, RA |
DMEM/F12, N2, B27, FGF2, and heparin |
GDNF, BDNF, and NT3 |
38 days |
| FGF2, and EGF | |||||||||
| Wichterle et al. [27] |
mESCs |
DFK5 medium (DMEM/F12, L-Glu, pen/strep, BME, and insulin-transferrin- selenium supplement |
RA, Shh, Hedgehog agonist (Hh-Ag1.3), or hedgehog antibody (5E1) |
Embryoid bodies |
DMEM/F12 medium |
- |
DMEM/F12 |
GDNF, BDNF, CNTF, and NT3 |
~25 days |
| Zeng et al. [47] | iPSC (ESCs as positive control) | hESC mediuma | N2 and heparin | Neural rosette | Neural mediumb | RA, Shh, and FGF8 | Neural basal medium, N2, and B27 | GDNF, BDNF, and IGF1 | >24 days |
aHuman embryonic stem cell (hESC) medium: Dulbecco’s modified Eagle’s medium (DMEM/F12), 20% knockout (KO) serum replacement, basal medium Eagle (BME), L-Glu, and non-essential amino acid (NEAA). bNeural induction medium: L-Glu, NEAA, penicillin/streptomycin (pen/strep), heparin, and N2. BDNF, brain-derived neurotrophic factor; bFGF, basic fibroblast growth factor; CNTF, ciliary neurotrophic factor; EGF, epidermal growth factor; ESC, embryonic stem cell; FGF, fibroblast growth factor; GDNF, glial cell-derived neurotrophic factor; HAG, human-specific Smo agonist; IGF1, insulin-like growth factor-1; iPSC, induced pluripotent stem cell; mESC, murine embryonic stem cell; MN, motor neuron; RA, retinoic acid; SAG, Smo agonist; Shh, Sonic hedgehog; smNPC, small-molecule neural precursor cell.